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ScienceDirectType 1 diabetes (T1D) is an autoimmune disease characterized
by the selective destruction of the insulin-producing beta cells.
Beta cell dysfunction caused by an inflammatory
microenvironment is believed to trigger the peripheral
activation of CD4 and CD8 autoreactive T cells. This review will
compile post-transcriptional and post-translational
modifications (PTM) involved in the generation of beta cell
neoantigens and proposes a reconstruction of the sequence of
events connecting environmental changes and autoimmunity.
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Introduction
Insulin producing beta cells are targeted by islet-
infiltrating immune cells that recognize beta cell
autoantigens in type 1 diabetes (T1D). Activated is-
let-autoreactive T cells occur in both circulation and
insulitic lesions [1,2,3], but it remains poorly under-
stood how these cells avoid thymic education, central
and peripheral tolerance and immune regulation, and
how they are primed. Improper presentation of self-
antigens by antigen-presenting cells due to low-affinity
native antigens may trigger these T cells to escape
thymic deletion [4–6]. Besides failures in central toler-
ance, it is conceivable that beta cells are key-players in
their own destruction by generating neoantigens avoid-
ing central tolerance [7].www.sciencedirect.com Accumulating evidence supports that local inflammation
surrounding the islet of Langerhans alters the beta cell
transcriptome and proteome, affecting the beta cell auto-
antigen repertoire [8]. In addition, beta cells are not just
passive victims but actively participate in a dialogue with
the immune compartment by locally releasing cytokines
and chemokines upon insulitis [9–11]; the human islet
architecture favors a direct cross talk between alpha and
beta cells, suggesting a participation of intra-islet com-
munication in balancing the islet micro-environment
[12,13]. Here, we will make the case for discordances
between the peripheral and thymic antigen repertoire to
contribute to the lack of, or break in, peripheral tolerance
by neoantigen-mediated beta cell destruction in T1D.
We will also attempt to position genetic predisposition to
disease, and link islet and macro-environment to the
generation of neoantigens and loss or lack of immune
tolerance. Finally, a connection between gut resident
pathogens and the course of T1D in relation to neoanti-
gens will be proposed [14].
Gene polymorphisms and post-transcriptional
modifications in autoimmune disease
Haplotypes at the human leukocyte antigen (HLA) loci
are strongly associated with genetic risk for T1D devel-
opment (in particular HLA-A2 and HLA-DQ). HLA
molecules dictate the repertoire of peptides to be pre-
sented to the immune system and shape the adaptive
immune system in the thymus. Genome wide association
studies identified an additional 40 common polymor-
phisms associated with T1D susceptibility [15]. Moreover,
genetic variations or single nucleotide polymorphisms
(SNPs) may affect regulatory elements or dictate RNA
splicing. In T1D, allelic variation in the variable number
of tandem repeats (VNTR) of the insulin gene were found
to correlate with thymic insulin expression dictating the
peripheral tolerance to insulin [4,16,17]. Also, SNPs in
cytotoxic T lymphocyte-associated protein 4 (CTLA4)
[18], expressed on the surface of activated CTLs and
crucial for regulating peripheral T cell responses, are
associated with a loss of self-tolerance. A SNP within
the CTLA4 30UTR led to an alteration in the ratio of
CTLA4 mRNA splice isoforms of the CTLA4 gene. This
shifted splicing efficiency correlated with increased dis-
ease susceptibility. We recently discovered that the same
SNP was associated with islet autoimmunity by affecting
CTLA4 mRNA stability [19]. Similarly, rare deleterious
variants in PTPN22 in T1D patients with multiple-
affected siblings were found to result in CD4T cellsCurrent Opinion in Immunology 2016, 43:67–73
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non-coding regions can alter regulatory elements such as
promoter sequences or 30 untranslated regions (UTRs).
This influences gene expression levels by interfering with
miRNA regulation [21], a mechanism of post-transcrip-
tional modification. In support of this, variation of func-
tional miRNA-binding elements within the 30-UTRs of
T1D-associated genes (CTLA4 and IL10) can have
consequences for regulation of T1D risk genes [22]. In
addition to genetic variations, post-transcriptional modi-
fications may contribute to autoimmune diseases by the
generation of antigens escaping tolerance induction. The
differential expression of IGRP variants between beta
cells versus thymus was shown to result in the generation
of islet neoantigens and the high immunogenicity against
these splice products detected in both non-diabetic and
type 1 diabetic subjects points to a lack of central tolerance
[23]. Alternative splicing of IA-2 led to differential IA-2
expression in the pancreas versus the thymus which may
underlie a permissive mechanism for the potential devel-
opment of autoimmunity against IA-2 [24].
Post-translational modifications of islet
antigens in type 1 diabetes
Post-translational modifications (PTM) increase the pro-
teome and affect epitope binding properties to HLA classFigure 1
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diseases by changing the intrinsic structural and electrical
properties of proteins or epitopes [25,26]. Polymorphic
HLA-DQ molecules predisposing to risk for autoimmune
diseases such as T1D favor certain peptide repertoires to
be presented to the immune system and modifications of
proteins and fragments may introduce peptide affinity,
locking such antigenic peptides into the HLA groove [27]
(Figure 1).
Animal models of autoimmune diabetes showed that
PTMs create new autoantigens recognized by diabeto-
genic T cells [28]. The first evidence of PTM in T1D in
humans involved chemical modification in the form of a
disulfide bond between adjacent cysteine residues on the
A chain of human insulin as a target of T cells [29].
Enzymes can create another range of modified antigenic
peptides. Tissue transglutaminase (tTG) is an enzyme
responsible for modifying gluten and gliadin into aller-
gens in coeliac disease by deamidation of glutamine into
glutamate. This enzyme is also present in relative high
levels in pancreatic islets [www.proteinatlas.org], but
becomes active in the context of inflammation [30].
Indeed, deamidated proinsulin was recently demonstrat-
ed in inflamed human islets of Langerhans [30]. We
recently showed that active tTG deamidates proinsulin,p9
E
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molecules [34]. T cell responses directed against deami-
dated proinsulin were observed in the majority of the
newly diagnosed T1D patients, compared to less than
half of the patients responding to native proinsulin.
Perhaps surprising, deamidated islet epitopes could also
be isolated from high-risk HLA class II of dendritic cells
pulsed with native islet antigens, implying that dendritic
cells, too, are able to post-translationally modify, process
and present deamidated neoepitopes and turn these into
potent autoantigens in T1D [33]. The increased tTG
activity in islet cells and dendritic cells suggests that tTG
is responsible for this inflammation-induced modification.
The conversion of (protein-bound) arginine into the non-
standard amino acid citrulline by peptidylarginine dei-
minases (PADs) is interesting in the context of autoim-
munity since PADs have not been detected in the thymus
[31], possibly excluding T cell education toward citrulli-
nated peptides. Citrullination of GAD65 peptides
enhances the binding to HLA-DR4; these peptide-
HLA complexes were recognized by autoreactive
CD4T cells isolated from T1D patients [25]. Also citrul-
linated glucose-regulated protein 78 was identified as a
modified autoantigen in murine beta cells and was a target
for autoreactive T cells in mice, indicating that PTM of
islets autoantigens is directly involved in beta cell de-
struction [32]. Recently, a new class of modification
wherein fusion peptides from non-contiguous peptide
fragments generate novel epitopes has been reported
to be involved in T1D [2]. In this study diabetogenic
CD4T cell clones isolated from non-obese diabetic mice
recognized epitopes consisting of proinsulin peptides
covalently crosslinked to other peptides present in insulin
secretory granules. This peptide fusion, thought to be
formed through a transpeptidation reaction, led to the
creation of hybrid insulin peptides that were detectable in
beta cells. CD4T cell lines from the residual pancreatic
islets of two type 1 diabetic pancreas donors also recog-
nize such hybrid peptides [2]. These types of neoanti-
gen generation may explain how immune tolerance is
broken in T1D (Figure 2).
An important function of PTM is regulation of protein
localization. Upon inflammation-induced ER stress, the
palmitoylation cycle of GAD65 is disrupted [33]. This
results in an aberrant endomembrane distribution and
accumulation of palmitoylated GAD65 in Golgi mem-
branes which accordingly triggers autoimmunity, presum-
ably by increased uptake and processing by APCs.
Although a role of autoantibodies in T1D pathology is still
unproven, insulin autoantibodies (IAA) remain the earli-
est marker of beta cell autoimmunity. Interestingly,
among the rare patients being IAA-negative, more than
30% were tested positive for autoantibodies against mod-
ified insulin [34]. The same group showed the presence of
autoantibodies against modified collagen [35], suggestingwww.sciencedirect.com that autoantibodies against modified islet antigens can
add significant value for (early) diagnosis of T1D. Yet,
humoral autoimmune responses to neoantigens have
largely been ignored. It is not inconceivable that auto-
antibodies to native self-proteins only represent the tip of
the iceberg. This assumption is corroborated by the
situation in other inflammatory diseases, such as coeliac
disease and rheumatoid arthritis.
The role of inflammatory cytokines in the
generation of islet neoantigens
During acute insulitis, the combined effect of proinflam-
matory cytokines and chemoattractants on beta cells leads
to hyperexpression of HLA class I, triggering beta cell
exposure to immune cells and the selective infiltration of
autoreactive CD8+ T cells [1]. More than just recruiting
immune cells to the inflammation site, inflammatory
signals interfere with cellular processes during conversion
of genetic information into proteins. At the RNA level,
IFN-g, IL1b combined treatment led to profound
changes in beta cell gene expression, including genes
involved in the splicing machinery [36,37]. As a conse-
quence, transcriptome analysis of purified human islets
maintained in proinflammatory cytokines has shown that
over 30% of the genes expressed in human islets undergo
alternative splicing, providing evidence for the genera-
tion of beta cell neo-autoantigen generation during insu-
litis [8].
Inflammatory cytokines perturb the intracellular calcium
level, affecting the ER homeostatic balance and activat-
ing Ca2+ dependent enzymes involved in post-transla-
tional modification (e.g., tTG and PAD [38,39]).
Recently, we have shown that supernatant of an activated
GAD65-specific CD4T cell clone induced post-transla-
tional modifications of human islet antigens and in par-
ticular, deamidated peptides derived from PPI were [30]
a prototype target for autoreactive T cells in T1D patients
[40,41]. Although the Unfolded Protein Response trig-
gered by ER stress is highly involved in PTM modifica-
tion in T1D [42], a prolonged exposure to metabolic or
inflammatory stress may also promote additional coping
mechanisms, including initiation of recycling programs by
vesicle formation [43]. In synoviocytes and monocytes
isolated from RA patients, m-TOR activation by Rapa-
mycin was shown to activate PAD activity in autophago-
somes and was proposed as mechanism for citrullination
[43].
The local inflammation is an important component of
beta cell destruction and in the generation of PTM
modified epitopes. However, the identity of pro-inflam-
matory cytokines in the vicinity of the inflamed beta cells
appears to determine the type and the intensity of beta
cell stress [44,45]. Unfortunately, studying the interplay
between the immune compartment and the islet com-
partment is challenging and our knowledge from the roleCurrent Opinion in Immunology 2016, 43:67–73
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affect the immune system. Cytokines and chemokines secreted by both innate immune cells and adaptive immune cells may interfere with the
communication between beta cells and other pancreatic cells and disturb post-transcriptional and post-translational fidelity in beta cells. Such
processes may contribute to the generation of modified autoantigens. Of note, environmental changes would also contribute to the generation of
autoantigens by modification of native proteins or peptides taken up and modified by dendritic cells.of cytokines in T1D, largely derived from studies in
rodent or cell lines with excessive un(patho)physiological
cytokine concentrations, lacks consistency. For example,
the mediators themselves (e.g., IFN-g or TNF alpha)
seem to both promote and prevent beta cell destruction
[46]. But more importantly, in humans the situation might
not be necessarily the same! Our view of the role of
cytokines in human T1D is limited and ‘in situ’ investiga-
tions, where biopsies from living subjects are analysed,
are rare but suggest that the amount of cytokines secreted
by infiltrating immune cells within T1D islets might have
been largely overestimated [47].
Inflammation also alters processing of the HLA class I
binding peptide repertoire. The subunits b1, b2, b5 from
the 20S proteasome catalytic domain are replaced under
inflammation by their inflammatory counterparts. Hence,Current Opinion in Immunology 2016, 43:67–73 the immunoproteasome formed may reshape the peptide
repertoire and the potential CTL response [48] by differ-
ent proteolytic activity, affecting processes like transpep-
tidation [49,50] that could contribute to ligandome
diversity. Of note, CD8 T-cell autoimmunity to modified
proteins has not yet been investigated in any detail in
humans, which is remarkable, given the large body of
recent evidence of CD4 T-cell autoimmunity against
PTM products.
The influence of the environment
Other pancreatic endocrine or exocrine cells have been
largely ignored in the selective beta cell destruction
process. Studies are supporting a guardian-type role of
alpha cells in particular, under stress stimulation by GLP-
1 secretion [51,52], but consequences of GLP-1 stimula-
tion or other incretins on the beta cell proteome stillwww.sciencedirect.com
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environment is relevant [53]. We recently discussed the
inverse relationship between the tumour microenviron-
ment and islets during insulitis [54].
The macro-environment also contributes to development
of T1D, and its effect on autoantigenesis should be
considered. The notion that approximately 50% of iden-
tical twins are discordant for T1D demonstrates that T1D
is not an inherited genetic disease and is largely influ-
enced by environmental factors, possibly acting in concert
with genetic risk factors [55]. The gut and the pancreas
are linked through a system in which gut-derived immune
and metabolic signals have the potential to induce effects
in the pancreas. The gut microbiome influences host
metabolism and immunity and might play a role in
T1D pathogenesis. Although profound changes in host
gene expression and proteome were observed following
enterovirus infection, the link between virus infection
and generation of beta cell neoantigens remains unestab-
lished. Similarly, recent microbiome analysis pointed to a
correlation between bacteria in Finnish and Estonian
infants and autoimmune diseases [56], indicating the
possible implication of a ‘gut storm’ in T1D pathology
[57]. Although a direct link with the generation of modi-
fied antigens in T1D was not tested, studies in coeliac
disease and rheumatoid arthritis revealed a direct effect of
microbial tTG from Streptoverticillium and PAD from
Porphyromonas gingivalis enzymes on PTM modification
of host substrates [58,59]. It is conceivable that such
processes may also occur in T1D.
The importance of the gut in the pathology of T1D is also
illustrated by the role of diet changes in autoimmune
development. Gluten free diet decreases intestinal in-
flammation and prevents CD development [60,61]. Simi-
larly, such nutritional intervention may impact the gut
microbiome and delay incidence of T1D as demonstrated
in rodents [62]. In patients with both CD and T1D, a
gluten-free diet improves glycaemic control in some
studies, but not consistently [63]. Children with anti-islet
cell autoimmunity presented an Akkermansia-dominated
gut microbiome resulting in higher levels of butyrate
production with subsequent protective effects on devel-
opment of T1D [64]. A relation with PTM is yet to be
investigated.
The question remains whether PTM provokes or results
from islet autoimmunity? Does the surrounding islet
micro-environment or macro-environment generate
PTM of islet antigens priming naı¨ve T cells? Intriguingly,
be it inconclusive, T-cell lines were generated against
modified, but not native proinsulin [65]. Once activated,
these T-cells cross-reacted with native proinsulin. This
could imply that PTM epitopes act as initial targets,
leading to the loss of tolerance in autoreactive T cells
in T1D patients.www.sciencedirect.com Concluding remarks
Modified islet epitopes are newly appreciated actors in
T1D pathogenesis. A better understanding of the pro-
cesses and micro-environmental and macro-environmen-
tal factors contributing to the generation of protein
modifications to which immune tolerance is lacking or
lost may prove essential for prevention or intervention of
type 1 diabetes. Appreciating the role of beta cells in their
own fate, in dialogue with other islets cells, the immune
system and the gut microbiome, has brought new dimen-
sions to deciphering changes in immune homeostasis in
the pancreas during insulitis. This is critical to define the
terms of loss of islet autoimmunity and the restoration of
immune tolerance.
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